Dr Tara Graff, DO, MS from Mission Cancer + Blood comments on updates in CLL and lymphoma from ASH 2022: Excellent PFS and efficacy with an all-oral regimen consisting of ibrutinib and venetoclax, and excellent responses with undetectable MRD in treatment naïve patients with or without high-risk (e.g., TP53 mutant) CLL using a triplet regimen (acalabrutinib + venetoclax + Obinutuzumab).
